0001209191-21-023480.txt : 20210329 0001209191-21-023480.hdr.sgml : 20210329 20210329191135 ACCESSION NUMBER: 0001209191-21-023480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210325 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duraibabu Prathyusha CENTRAL INDEX KEY: 0001779092 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 21783117 MAIL ADDRESS: STREET 1: C/O SANGAMO THERAPEUTICS, INC. STREET 2: 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001779092 Duraibabu Prathyusha C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 0 1 0 0 VP, PFO and PAO Common Stock 2021-03-25 4 F 0 345 12.27 D 40790 D Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on March 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on March 25, 2021 of $12.27/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). Includes: (a) 655 shares resulting from the March 25, 2021 vesting of the Reporting Person's March 25, 2020 RSU grant and 2,000 shares subject to such RSU grant that will vest in two remaining annual installments of 1,000 shares and 1,000 shares on March 25, 2022 and 2023 respectively; (b) 3,833 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; (c) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; and (d) 44,000 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. /s/ Matthew Colvin, Attorney-in-Fact for Prathyusha Duraibabu 2021-03-29